Literature DB >> 20454510

Comparison of tumor and microenvironment secretomes in plasma and in platelets during prostate cancer growth in a xenograft model.

Bethany A Kerr1, Ranko Miocinovic, Armine K Smith, Eric A Klein, Tatiana V Byzova.   

Abstract

To survive and metastasize, tumors interact with surrounding tissues by secreting growth factors and cytokines. In return, surrounding host tissues respond by changing their secretome. Numerous factors theoretically function as therapeutic targets or biomarkers of cancer growth and metastatic risk. However, it is unclear if these factors are tumor-derived or actually represent the host defense. To analyze the concentrations of tumor- and microenvironment-derived factors associated with neoplastic growth, we used ELISA-based arrays specific for murine or human proteins to establish a profile of tumor- or host-derived factors circulating in the plasma or within the platelets upon human tumor implantation into mice. Many factors characterized as tumor-derived were actually secreted by host tissues. This study uncovered the origin of various cytokines and revealed their circulation methods. We found that tumor-produced cytokines are predominantly sequestered in platelets. Sequestered proteins are protected from degradation and, thus, may be functional at metastatic sites. These findings identify tumor-specific targets for the detection and prevention of tumor growth and metastasis. As predicted by our model, monocyte chemotactic protein 1 and tumor necrosis factor alpha may be biomarkers for human cancers. Thus, our study identified several potential biomarkers that might be predictive of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20454510      PMCID: PMC2864476          DOI: 10.1593/neo.10166

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  28 in total

Review 1.  Osteoclast differentiation and activation.

Authors:  William J Boyle; W Scott Simonet; David L Lacey
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

2.  Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma.

Authors:  H L Adler; M A McCurdy; M W Kattan; T L Timme; P T Scardino; T C Thompson
Journal:  J Urol       Date:  1999-01       Impact factor: 7.450

3.  Networking in the hemostatic system. Integrin alphaiibbeta3 binds prothrombin and influences its activation.

Authors:  T V Byzova; E F Plow
Journal:  J Biol Chem       Date:  1997-10-24       Impact factor: 5.157

4.  Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis.

Authors:  L Borsig; R Wong; J Feramisco; D R Nadeau; N M Varki; A Varki
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

5.  Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor.

Authors:  P Salven; A Orpana; H Joensuu
Journal:  Clin Cancer Res       Date:  1999-03       Impact factor: 12.531

6.  Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer.

Authors:  Giuseppe Morgia; Mario Falsaperla; Grazia Malaponte; Massimo Madonia; Manuela Indelicato; Salvatore Travali; Maria Clorinda Mazzarino
Journal:  Urol Res       Date:  2004-10-22

7.  Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma.

Authors:  L Manenti; P Paganoni; I Floriani; F Landoni; V Torri; A Buda; G Taraboletti; R Labianca; D Belotti; R Giavazzi
Journal:  Eur J Cancer       Date:  2003-09       Impact factor: 9.162

8.  Osteoblast-derived factors induce an expression signature that identifies prostate cancer metastasis and hormonal progression.

Authors:  Gang Wang; Simon Haile; Barbara Comuzzi; Amy H Tien; Jun Wang; Theresa M K Yong; Anca E Jelescu-Bodos; Natalie Blaszczyk; Robert L Vessella; Bassam A Masri; Marianne D Sadar
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

9.  Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo.

Authors:  S Karpatkin; E Pearlstein; C Ambrogio; B S Coller
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

10.  Thrombospondin causes activation of latent transforming growth factor-beta secreted by endothelial cells by a novel mechanism.

Authors:  S Schultz-Cherry; J E Murphy-Ullrich
Journal:  J Cell Biol       Date:  1993-08       Impact factor: 10.539

View more
  18 in total

1.  The interconnectedness of cancer cell signaling.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

2.  Blood platelets contain tumor-derived RNA biomarkers.

Authors:  R Jonas A Nilsson; Leonora Balaj; Esther Hulleman; Sjoerd van Rijn; D Michiel Pegtel; Maudy Walraven; Anders Widmark; Winald R Gerritsen; Henk M Verheul; W Peter Vandertop; David P Noske; Johan Skog; Thomas Würdinger
Journal:  Blood       Date:  2011-08-10       Impact factor: 22.113

3.  Dinosaurs and ancient civilizations: reflections on the treatment of cancer.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2010-12       Impact factor: 5.715

4.  Renal cell carcinoma and tumour thrombus in the inferior vena cava: clinical outcome of 98 consecutive patients and the prognostic value of preoperative parameters.

Authors:  Christian Niedworok; Bettina Dörrenhaus; Frank Vom Dorp; Jarowit Adam Piotrowski; Stephan Tschirdewahn; Tibor Szarvas; Herbert Rübben; Marcus Schenck
Journal:  World J Urol       Date:  2014-11-30       Impact factor: 4.226

5.  Global secretome analysis identifies novel mediators of bone metastasis.

Authors:  Mario Andres Blanco; Gary LeRoy; Zia Khan; Maša Alečković; Barry M Zee; Benjamin A Garcia; Yibin Kang
Journal:  Cell Res       Date:  2012-06-12       Impact factor: 25.617

Review 6.  Carpe low-dose aspirin: the new anti-cancer face of an old anti-platelet drug.

Authors:  Annachiara Mitrugno; Joanna L Sylman; Rachel A Rigg; Samuel Tassi Yunga; Joseph J Shatzel; Craig D Williams; Owen J T McCarty
Journal:  Platelets       Date:  2017-12-21       Impact factor: 3.862

7.  Platelet TSP-1 controls prostate cancer-induced osteoclast differentiation and bone marrow-derived cell mobilization through TGFβ-1.

Authors:  Bethany A Kerr; Koran S Harris; Lihong Shi; Jeffrey S Willey; David R Soto-Pantoja; Tatiana V Byzova
Journal:  Am J Clin Exp Urol       Date:  2021-02-15

8.  Platelets govern pre-metastatic tumor communication to bone.

Authors:  B A Kerr; N P McCabe; W Feng; T V Byzova
Journal:  Oncogene       Date:  2013-09-15       Impact factor: 9.867

Review 9.  The prothrombotic activity of cancer cells in the circulation.

Authors:  Annachiara Mitrugno; Garth W Tormoen; Peter Kuhn; Owen J T McCarty
Journal:  Blood Rev       Date:  2015-07-14       Impact factor: 8.250

10.  Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2012-12       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.